According to Mediclin's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 19.611. At the end of 2023 the company had a P/E ratio of -11.9.
Year | P/E ratio | Change |
---|---|---|
2023 | -11.9 | -166.18% |
2022 | 18.0 | -86.22% |
2021 | 131 | -739.86% |
2020 | -20.4 | -179.31% |
2019 | 25.8 | -28.35% |
2018 | 35.9 | -54% |
2017 | 78.1 | 365.82% |
2016 | 16.8 | 41.34% |
2015 | 11.9 | -39.67% |
2014 | 19.7 | -127.47% |
2013 | -71.6 | -48.25% |
2012 | -138 | -321.93% |
2011 | 62.3 | 208.73% |
2010 | 20.2 | 47.08% |
2009 | 13.7 | -2.58% |
2008 | 14.1 | -9.09% |
2007 | 15.5 | 8.64% |
2006 | 14.3 | 48.37% |
2005 | 9.62 | -373.99% |
2004 | -3.51 | -4.62% |
2003 | -3.68 |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.